Sugi Predict

Sugi Predict / Compounds / Amadinone Acetate

Amadinone Acetate

Amadinone Acetate

SCHEMBL282893

CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 7/20 0.81
▸ AR P10275 7/20 0.81
▸ PGR P06401 7/20 0.81
▸ PDE4D Q08499 1/20 0.81
▸ CYP3A4 P08684 8/20 0.66
▸ SMN1; SMN2 Q16637 4/20 0.66
▸ MAPK1 P28482 4/20 0.66
▸ CHRM2 P08172 4/20 0.66
▸ ALDH1A1 P00352 3/20 0.66
▸ NPSR1 Q6W5P4 3/20 0.66
▸ CHRM1 P11229 3/20 0.66
▸ CYP2C19 P33261 3/20 0.66
▸ HIF1A Q16665 2/20 0.66
▸ USP2 O75604 2/20 0.66
▸ ADORA3 P0DMS8 2/20 0.66
▸ TBXA2R P21731 2/20 0.66
▸ ADRA1A P35348 2/20 0.66
▸ THRB P10828 1/20 0.66
▸ LMNA P02545 5/20 0.58
▸ CYP2C9 P11712 4/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nomegestrol Acetate SCHEMBL19760877 0.89 PGR (1.00) NR3C1ARPGRPDE4DCYP3A4
Nomegestrol Acetate SCHEMBL37517 0.89 PGR (1.00) NR3C1ARPGRPDE4DCYP3A4
Nomegestrol Acetate SCHEMBL8817628 0.89 PGR (1.00) NR3C1ARPGRPDE4DCYP3A4
SCHEMBL8626100 0.87 PGR (0.81) NR3C1ARPGRPDE4DCYP3A4
SCHEMBL28501809 0.87 PGR (0.81) NR3C1ARPGRPDE4DCYP3A4
SCHEMBL141181 0.84 CYP2C19 (0.64) NR3C1ARPGRPDE4DCYP3A4
Acetic Acid SCHEMBL282894 0.82 CYP2C19 (0.62) NR3C1ARPGRPDE4DCYP3A4
SCHEMBL10952461 0.80 PGR (0.67) NR3C1ARPGRPDE4DCYP3A4
SCHEMBL20266962 0.80 PGR (0.67) NR3C1ARPGRPDE4DCYP3A4
Chlormadinone Acetate SCHEMBL4948575 0.79 AR (1.00) NR3C1ARPGRPDE4DCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 452 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160008376-A1 Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders BIOCOPEA LIMITED (GB) 2016-01-14 — — US claimed
WO-2016005599-A1 COMPOSITIONS, METHODS AND USES FOR TREATING GENDER-BIASED IMMUNE DISORDERS BIOCOPEA LIMITED (GB) 2016-01-14 — — WO claimed
US-8268352-B2 Modified release composition for highly soluble drugs TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-18 — — US claimed
US-8263125-B2 Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-11 — — US claimed
US-20060024365-A1 Novel dosage form VAYA NAVIN 2006-02-02 — — US claimed
US-20060018933-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 — — US claimed
US-20060018934-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 — — US claimed
EP-4706683-A2 CHEWABLE FORMULATIONS Elanco Tiergesundheit AG (CH) 2026-03-11 — — EP disclosed
US-20260034059-A1 ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES AQUESTIVE THERAPEUTICS, INC. (US) 2026-02-05 — — US disclosed
US-12465564-B2 Oral and nasal compositions and methods of treatment AQUESTIVE THERAPEUTICS, INC. (US) 2025-11-11 — — US disclosed
US-20250339367-A1 ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES AQUESTIVE THERAPEUTICS, INC. (US) 2025-11-06 — — US disclosed
US-12403090-B2 Oral film compositions and dosage forms having precise active dissolution profiles AQUESTIVE THERAPEUTICS, INC. (US) 2025-09-02 — — US disclosed
US-20250255780-A1 SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES AQUESTIVE THERAPEUTICS, INC. (US) 2025-08-14 — — US disclosed
US-5795909-A ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS NEUROMEDICA, INC. (US) 1998-08-18 — — US disclosed
WO-1998028264-A1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER INC. (US) 1998-07-02 — — WO disclosed
CN-1178668-A Cooperate therepeutic-pregnendione and estrin excitant for preventing bony defect PFIZER (US) 1998-04-15 — — CN disclosed
WO-1997044063-A2 DHA-PHARMACEUTICAL AGENT CONJUGATES NEUROMEDICA, INC. (US) 1997-11-27 — — WO disclosed
CN-1165654-A Combination therapy to treat osteoporosis-polyphosphonates or progesting and extrogen agonists PFIZER (US) 1997-11-26 — — CN disclosed
EP-0792645-A1 Combination therapy to treat osteoporosis PFIZER INC. (US) 1997-09-03 — — EP disclosed
EP-0791356-A1 Combinations of droloxifene with progestins for the treatment of osteoporosis PFIZER INC. (US) 1997-08-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034059-A1 ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES SORD, SLC6A13, CACNA1A NR3C1 4229/4885AR 3963/4885PGR 2541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.